Several clinical trials have tested enzalutamide in combination with endocrine therapy in ERα-positive and/or PR-positive breast cancer and have determined that these are well tolerated (NCT01597193; NCT02953860) [107,109]. The gene discussed is PGR; the disease is breast cancer.